Tirofiban Infusion Dosing
The current FDA-approved and guideline-recommended dosing for tirofiban is a 25 mcg/kg IV bolus administered over 5 minutes, followed by a maintenance infusion of 0.15 mcg/kg/min for up to 18 hours. 1
Standard Dosing (Normal Renal Function)
For patients with creatinine clearance (CrCl) >60 mL/min:
- Loading dose: 25 mcg/kg IV bolus over 5 minutes
- Maintenance infusion: 0.15 mcg/kg/min for up to 18 hours
This represents increased dosing over previous recommendations and is the current standard for patients undergoing PCI in the setting of NSTE-ACS or STEMI. 2, 3, 4, 5
Dose Adjustment for Renal Impairment
For patients with CrCl ≤60 mL/min:
- Loading dose: 25 mcg/kg IV bolus over 5 minutes (unchanged)
- Maintenance infusion: 0.075 mcg/kg/min (50% reduction) for up to 18 hours
Calculate CrCl using the Cockcroft-Gault equation with actual body weight. 1
Critical caveat: For patients with CrCl <30 mL/min, some guidelines recommend reducing the infusion rate by 50%, though the FDA label specifies the 0.075 mcg/kg/min dose for all patients with CrCl ≤60 mL/min. 3, 6, 7
Practical Calculation
Using the 250 mL premixed bag (50 mcg/mL concentration):
Bolus volume (mL) = Patient weight (kg) × 0.5
Infusion rate for CrCl >60 mL/min (mL/hr) = Patient weight (kg) × 0.18
Infusion rate for CrCl ≤60 mL/min (mL/hr) = Patient weight (kg) × 0.09
Example for 70 kg patient with normal renal function:
- Bolus: 35 mL over 5 minutes
- Maintenance: 12.6 mL/hr
Alternative Lower-Dose Regimen (FDA-Approved)
An older, lower-dose regimen remains FDA-approved for medical management when there is substantial delay to angiography/PCI (e.g., 48 hours):
- Loading dose: 0.4 mcg/kg/min for 30 minutes
- Maintenance infusion: 0.1 mcg/kg/min
- Continue through angiography and for 12-24 hours after intervention
This regimen is less commonly used in contemporary practice but may be considered in specific clinical scenarios. 3, 4, 5
Duration and Timing
- Duration: Up to 18 hours at physician discretion (12-18 hours commonly cited)
- Initiation: Can be given before, during, or after PCI depending on clinical scenario
- Discontinuation: Typically stopped 4-8 hours before planned surgery if bridging antiplatelet therapy 8
Important Safety Considerations
Monitor platelet counts beginning approximately 6 hours after treatment initiation and daily thereafter. If platelets drop below 90,000/mm³, exclude pseudothrombocytopenia and consider discontinuation if true thrombocytopenia is confirmed. 1
Bleeding risk is the primary concern—most bleeding occurs at arterial access sites. The higher-dose regimen (25 mcg/kg bolus) has replaced older protocols because it provides more consistent platelet inhibition without significantly increased bleeding when used appropriately. 2, 3, 9
Renal dosing is critical—failure to reduce the maintenance infusion in renal impairment significantly increases bleeding risk due to prolonged drug half-life. 6, 10, 7